Please provide your email address to receive an email when new articles are posted on . CHICAGO — The voluntary withdrawal of CyPass from the global market shocked the field of ophthalmology, but the ...

Wall Street analysts are weighing in on Glaukos Corp (NASDAQ: GKOS) Wednesday after the stock jumped more than 30 percent thanks to a major competitor removing its product from the market. Alcon ...

Sydney L. Tyson, M.D., MPH (right) lectures lectures about the CyPass Micro-Stent to ophthalmologists and optometrists at the South Jersey Society of Optometric Physicians' meeting at the SurgiCenter ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Trimming or removing the CyPass micro-stent is recommended for patients who are experiencing ...

(RTTNews) - Alcon, the eye care unit of Novartis (NVS), announced Wednesday an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. Alcon also advised surgeons to ...

A US Food and Drug Administration (FDA) safety communication was escalated to a Class I recall for Alcon’s CyPass micro-stent systems over risk of eye damage in implanted patients. The updates come in ...

Purpose: To evaluate safety and clinical outcomes of a novel supraciliary device, the CyPass Micro-Stent, for surgical treatment of open-angle glaucoma when implanted in conjunction with cataract ...

Alcon, the eye care division of Novartis, said this week it is pulling all versions of its CyPass micro-stent from the global market based on the results of a five-year post-approval study. The ...

MENLO PARK, CA--(Marketwired - October 22, 2015) - Transcend Medical, Inc., a pioneer of minimally invasive glaucoma surgery (MIGS), today announced the submission to the U.S. Food and Drug ...

Shares of Glaukos Corporation (NYSE: GKOS), a mid-cap ophthalmic medical technology and pharmaceutical company, spiked by as much as 63.7% today on heavy volume. The spark? Glaukos shares are rising ...

CHICAGO — For the treatment of primary open-angle glaucoma (OAG), the CyPass Micro-Stent procedure appears safe and effective in lowering intraocular pressure (IOP) for at least 12 months, both as a ...